06/24/2026
A pre-revenue biotech founder once told us his burn rate update for investors was going well because nobody had pushed back on it. What he was actually doing was reporting how much cash left the account every month and calling it strategy.
Investors are not just looking at the number, they are looking for evidence it reflects decisions. Gross burn is everything going out the door, payroll, lab costs, contract research, and it is usually the figure that should drive runway planning, not net burn after whatever grant funding trickles in. Runway itself falls apart fast if you calculate it off last month's average instead of what spending will actually look like over the next 12 to 18 months, especially once a trial moves phases or a hiring wave hits ahead of a raise.
What investors are really evaluating is whether the founder understands the relationship between spending and milestones, whether dollars are going toward de-risking the science or just keeping the lights on. The founders who handle this well treat burn rate as something they revisit monthly, not a slide they build before a board meeting.
Follow for more financial content built for biotech and life sciences founders.